Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow 4D Molecular Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for 4D Molecular Therapeutics, Inc.

FDMT

4D Molecular Therapeutics, Inc.

About 4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc. is a late-stage biotechnology company specializing in innovative genetic medicines for ophthalmology and pulmonology. Its lead product, 4D-150, targets retinal diseases like wet AMD and diabetic macular edema, while 4D-710 aims to treat cystic fibrosis. Utilizing its proprietary Therapeutic Vector Evolution platform, the company addresses significant unmet medical needs, focusing on durable therapies with reduced treatment burdens. 4DMT is positioned for impactful advancements in patient care.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from 4D Molecular Therapeutics, Inc.

1
1
4D Molecular Therapeutics, Inc. 4D Molecular Therapeutics Reports Q1 2026 Financial Results with Increased Revenue and Significant Losses

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
4D Molecular Therapeutics, Inc. 4D Molecular Therapeutics Reports $85.2 Million Revenue Growth and $140.1 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
4D Molecular Therapeutics, Inc. 4D Molecular Therapeutics Reports $56.9 Million Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
4D Molecular Therapeutics, Inc. 4D Molecular Therapeutics Reports $54.7 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
4D Molecular Therapeutics, Inc. 4D Molecular Therapeutics Reports $48M Net Loss and Decreased Revenue in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
4D Molecular Therapeutics, Inc. 4D Molecular Therapeutics Reports $160.9 Million Net Loss and Significant Revenue Decline in 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
4D Molecular Therapeutics, Inc. 4D Molecular Therapeutics Reports Significant Financial Decline, Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments